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High expression of MKP1/DUSP1
counteracts glioma stem cell activity and
mediates HDAC inhibitor response
Olatz Arrizabalaga1, Leire Moreno-Cugnon1, Jaione Auzmendi-Iriarte1, Paula Aldaz1,2, Inmaculada Ibañez de Cáceres3,
Laura Garros-Regulez1, Veronica Moncho-Amor4, Sergio Torres-Bayona5, Olga Pernía3, Laura Pintado-Berninches6,
Patricia Carrasco-Ramirez6, María Cortes-Sempere6, Rocío Rosas3, Pilar Sanchez-Gomez7, Irune Ruiz1,2,5, Helena Caren8,
Steven Pollard9, Idoia Garcia1,2,10, Angel-Ayuso Sacido11, Robin Lovell-Badge 4, Cristobal Belda-Iniesta11,
Nicolas Sampron1,2,5, Rosario Perona6,12 and Ander Matheu1,2,10
Abstract
The elucidation of mechanisms involved in resistance to therapies is essential to improve the survival of patients with
malignant gliomas. A major feature possessed by glioma cells that may aid their ability to survive therapy and
reconstitute tumors is the capacity for self-renewal. We show here that glioma stem cells (GSCs) express low levels of
MKP1, a dual-specificity phosphatase, which acts as a negative inhibitor of JNK, ERK1/2, and p38 MAPK, while induction
of high levels of MKP1 expression are associated with differentiation of GSC. Notably, we find that high levels of MKP1
correlate with a subset of glioblastoma patients with better prognosis and overall increased survival. Gain of
expression studies demonstrated that elevated MKP1 impairs self-renewal and induces differentiation of GSCs while
reducing tumorigenesis in vivo. Moreover, we identified that MKP1 is epigenetically regulated and that it mediates the
anti-tumor activity of histone deacetylase inhibitors (HDACIs) alone or in combination with temozolomide. In
summary, this study identifies MKP1 as a key modulator of the interplay between GSC self-renewal and differentiation
and provides evidence that the activation of MKP1, through epigenetic regulation, might be a novel therapeutic
strategy to overcome therapy resistance in glioblastoma.
Introduction
Glioblastoma is the most common and malignant brain
cancer in adults, which is characterized by its intrinsic
aggressiveness and dismal prognosis1. Current therapy
consisting of surgery followed by radiotherapy and che-
motherapy with temozolomide has partial effectiveness,
but the tumor recurs. Thus, overall patient survival is
15 months and percentage of survivors at 3 years is
around 5%2. Glioblastoma is characterized by significant
heterogeneity at clinical, morphological, molecular
genetic, and cellular levels, and this heterogeneity is a
major explanation for the poor prognosis. In particular, it
has been demonstrated that treatment failure is due to the
inability of current therapies to eliminate a subpopulation
of glioma cells, with stem cell characteristics called glioma
stem cells (GSCs)3. GSCs contain self-renewal capacity
and can give rise to the various cell lineages that comprise
the tumor4–7; therefore, they have been postulated as
responsible for the origin, maintenance recurrence, and
drug resistance of glioblastoma8.
Mitogen-activated protein kinases (MAPKs) are protein
kinases involved in intracellular signaling during pro-
liferation, differentiation apoptosis, and cell stress
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responses. Activation of MAPKs, involving ERK1/2, p38
MAPK, JNK, has been implicated in the development and
progression of several cancers, including glioblastoma9–11,
and for resistance to chemotherapeutic DNA-methylating
agents12, 13. Recently, it has been found that the activation
of MAPKs is necessary for GSCs self-renewal activity, the
ability to initiate tumors and radioresistance14–17, leading
to the evidence that GSCs maintenance via MAPKs is a
major step in the progression and therapy resistance of
glioblastoma.
MAP kinases are regulated by the family of MAPK
phosphatases (MKPs), also called dual-specificity phos-
phatases (DUSPs), which are able to dephosphorylate
both the threonine and tyrosine residues in conserved
motifs, thereby inhibiting their activity18. Among them,
MKP1/DUSP1 is expressed ubiquitously and its tran-
scription increases rapidly in response to growth factors,
oxidative stress, heat, hormones, cytokines, osmotic stress,
hypoxia, and chemical and physical DNA damage. MKP1
has nuclear localization and its major substrates are JNK,
p38 MAPK, and ERK1/2. The preference for each of these
substrates is dependent on the tissue or also specific cell
types. MKP1 plays an important role in oncogenesis,
tumor progression, and resistance to chemotherapy in
cancers such as ovarian, lung, or breast19–21. However, its
function in cancer stem cells has not been identified and
its role in glioblastoma remains unknown.
Results
High levels of MKP1 correlate with extended glioblastoma
patient survival
We first analyzedMKP1 expression levels by RT-PCR in
a set of glioma cell lines and found that MKP1 expression
was generally low on glioma cells compared to normal
brain tissue (Fig. 1a). Next, we moved to patient-derived
GSCs observing that four different cultures, two grown as
adherent lines (GNS166, GNS179) and another two as
oncospheres (GB2 and GB1) expressed even lower MKP1
messenger RNA (mRNA) levels than conventional glioma
cell lines and healthy brain tissue (Fig. 1a).
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Fig. 1 High levels of MKP1 correlate with extended glioblastoma patient survival. a MKP1 mRNA levels were assayed in a set of healthy brain
tissues as control (n = 6), glioma cell lines (U87MG, U373MG, U251, A172, and T98), and patient-derived GSC cell lines (GNS166, GNS179, GB2, and
GB1). qRT-PCR data are normalized to GAPDH expression. b MKP1 mRNA levels were assayed in a cohort including a set of healthy brain tissue as
control (n = 6) and glioma samples (n = 59, 44 of them were GBM). qRT-PCR data are normalized to GAPDH expression and expression in tumors is
relative to healthy brain tissue. c Analysis of the correlation of MKP1 expression with different glioma grade samples in two independent cohorts. d
Kaplan–Meier curve representing the survival of the GBM patients relative to their MKP1 expression levels (n = 44). e Kaplan–Meier curve representing
the survival of the GBM patients relative to their MKP1 expression levels (n = 25)
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We also studied MKP1 expression levels in a set of
glioma human samples containing grade II–IV biopsies
and compared them to non-neoplastic brain tissue from
Valencia Hospital (cohort 1) (Supplementary Fig. 1). Our
study revealed low (fold change below 0.5) levels ofMKP1
in few grade II and III gliomas, whereas 45% of glio-
blastomas (20 of 44) displayed low MKP1 (Fig. 1b, c). The
expression of MKP1 in biopsies obtained from patients
with GBM recurrence was also very low (Fig. 1b). More-
over, we determinedMKP1 expression on an independent
set of samples from Donostia Hospital (cohort 2), finding
similar frequency (14 of 25, 56%) of glioblastomas pre-
senting low expression of MKP1 (Fig. 1c). When we
correlated MKP1 expression to clinical information, we
found that high levels were associated with increased
glioblastoma patient overall survival in both cohorts (log
rank p= 0.04 and 0.007, respectively) (Fig. 1d, e). Indeed,
median overall survival of patients with high levels of
MKP1 was 14 and 18 months in cohort 1 and 2, compared
to 9 and 6 with low MKP1, respectively. Together, these
results show that MKP1 mRNA expression is generally
low in tumor samples, lower levels are associated with
advanced glioma grade, but these low levels of MKP1
correlate with poor overall patient survival underlining
the impact of MKP1 expression as an independent glio-
blastoma prognostic marker.
High levels of MKP1 correlate with GSC differentiation
To investigate the association of MKP1 to cellular het-
erogeneity, we checked its expression in several
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Fig. 2 High levels of MKP1 correlate with GSCs differentiation. a Analysis of the MKP1 mRNA expression levels in GSC lines grown in stem
medium compared to differentiation conditions (n = 3). b MKP1 mRNA expression by RNA-seq analysis in G26 and NS-1 cells at 8, 32, and 64-day time
course of BMP treatment after GF withdrawal (GF). Error bars denote SD of four independent experiments. c Frequency of MKP1 promoter
methylation after BMP4 continous treatment at the indicated time points. d mRNA expression of MKP1 was analyzed in U87 and GNS166 lines under
increasing 5-AZA concentrations. e Analysis of MKP1 mRNA expression levels in U251 cells with knockdown of SOX2 (shSOX2) or SOX9 (shSOX9)
related to the control (pLKO) condition (n = 3). qRT-PCR data are normalized to GAPDH expression. f MKP1 levels in U87 cells with SOX2 or SOX9
overexpression compared to control cells (n = 3). g Association analysis of MKP1 with SOX2 and SOX9 in the human glioblastoma TCGA cohort from
R2: Genomics Analysis and Visualization Platform http://r2.amc.nl. The analysis showed a negative correlation between MKP1 and SOX2 (R −0.207, p
value 1.3e−06), and MKP1 and SOX9 (R −0.169, p value 1.7e−04)
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differentiation conditions, starting with the addition of 1%
serum. Of note, MKP1 levels increased significantly in the
four studied GSC lines in a range from 2.5- to 15-fold
change after 7 days in the presence of serum (Fig. 2a).
GSC exposure to BMP4 induces differentiation both
in vitro and in vivo22. Therefore, we assessed the
expression of MKP1 in GSCs cultured in the presence of
BMP423. Interestingly, RNA sequencing identified MKP1
within the genes upregulated upon BMP4 induced-
differentiation in a GSC line (G26) but also in neural
stem cell controls (NS-1) (Fig. 2b). Indeed, the kinetics of
transcriptional MKP1 expression shows an increase from
225 reads after growth factor withdrawal from culture
media to 802 and 732 following 32 and 64 days of con-
tinuous BMP treatment in G26 cells (Fig. 2b). Moreover,
DNA methylation assay revealed that theMKP1 promoter
is demethylated at CpG islands during BMP4 treatment in
a time course-dependent manner in G26 cells (Fig. 2c)
These results suggest that increased expression of MKP1
during differentiation is dependent on DNA demethyla-
tion of the promoter. To further characterize this idea, we
treated both conventional glioma lines and GSCs with the
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Fig. 3 MKP1 overexpression inhibits glioma cell tumorigenicity. a mRNA levels of MKP1 in U87 and U373 cells transduced with the indicated
conditions (n = 3). b Cell growth assay comparing control and MKP1-overexpressing U87 and U373 cells (n = 3). c Representative image and
quantification of P-H3+ cells in control and MKP1-overexpressing U373 cells (n = 3). d 2.5×105 non-transduced, empty vector (control) and MKP1-
transduced U87 cells were injected subcutaneously in nude mice (n = 8 per condition) and volume of the tumors was scored at the indicated time
points. e Representative images and quantification of the immunohistochemical staining of Ki67 in tumors from d (n = 3). f Quantification of 1ry
oncospheres forming capacity in MKP1-infected U373 and U87 cells after 10 days in culture. The numbers are relative to control cells (n = 3). g
Quantification of 2ry oncospheres derived from MKP1 U373 and U87 cells. The numbers are relative to control cells (n = 3). h CD133, SOX9, and SOX2
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DNA methylation inhibitor 5-AZA. Our results revealed
marked induction in MKP1 levels with increasing con-
centrations of 5-AZA in U87 and GNS166 cells (Fig. 2d).
Since we observed an inverse correlation betweenMKP1
expression and GSC activity in the presence of serum and
BMP4, we further studied the association between MKP1
and GSCs, checking the expression of MKP1 in cells with
genetic knockdown of SOX2 and SOX9 stem cell factors,
which displayed impaired self-renewal24. MKP1 was ele-
vated by >2.5-fold in cells with knockdown of SOX2 or
SOX9 (Fig. 2e). On the contrary, MKP1 levels were
reduced in glioma cells with elevated SOX2 or SOX9
activity (Fig. 2f). In line with this evidence, association
analysis in the human glioblastoma cohort from the
TCGA showed an inverse correlation between MKP1 and
SOX2 (r=−0.207, p value= 1.3e−06) and also with SOX9
(r=−0.169, p value= 1.7e−04) (Fig. 2g). These results
further demonstrate the positive correlation between
MKP1 and differentiation of GSCs and reveal that the
expression of MKP1 in GSCs is affected by epigenetic
changes and also transcriptionally through, at least, SOX2
and SOX9 transcription factors. This latter effect seems to
be specific for GSCs as there is no correlation (negative or
positive) between MKP1, SOX2, and SOX9 expression in
healthy brain tissue (Supplementary Fig. 2).
MKP1 overexpression inhibits glioma cell tumorigenicity
Given that clinically high expression of MKP1 positively
correlates with patient survival, we overexpressed MKP1 in
glioma cell lines expressing low endogenous levels to test the
biological consequences of elevating MKP1 levels with
respect to different processes associated with cancer. For
this, U87 and U373 cells were transduced with a plasmid
encoding MKP1 and stable MKP1 overexpression estab-
lished in these cells (Fig. 3a). First, we observed that high
levels of MKP1 significantly reduced cellular growth
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cells in both control and MKP1-overexpressing GNS166 cells (n = 3). d SOX2, SOX9, OCT4, and GFAP mRNA expression levels in GNS166 with ectopic
activation of MKP1 relative to controls (n = 3). e Representative immunoblots of SOX2 and SOX9 derived from two different and independent
retroviral infections. f Expression of TUJ1 and CNPase in GNS166 with ectopic MKP1 relative to control transduced cells (n = 3). g Representative
images of TUJ1+- and CNPase+-infected GNS166 cells (n = 3) after 7 days cultured under differentiation conditions. h Control and MKP1 GNS166 cells
were injected stereotaxically in nude mice (n = 5 and 3) and growth of the tumors was scored 120 days after
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(Fig. 3b). Moreover, we analyzed proliferative ability finding
that MKP1 cells exhibited lower rate of proliferation, mea-
sured by phospho-Histone3 (P-H3) staining, compared to
control cells (Fig. 3c). In order to further investigate whether
MKP1 might regulate tumor cell proliferation and activity,
U87 parental, empty vector, or MKP1-transduced cells were
injected subcutaneously in immunodeficient mice. Of note,
there was a delay in tumor formation and a significant
decrease in tumor growth in MKP1-overexpressing cells
compared to controls or U87 parental cells (Fig. 3d).
Moreover, the impaired tumorigenic ability of MKP1 cells
was corroborated by immunohistochemistry analysis in the
tumors in vivo. Indeed, MKP1-derived xenografts possessed
lower numbers of Ki67-positive cells than tumors derived
from control cells (Fig. 3e). These data reveal that elevated
expression of MKP1 suppresses glioma cell tumorigenicity.
U87 and U373 cell lines present a subpopulation of cells
with stem cell characteristics that grow as oncospheres24.
We therefore cultured control andMKP1-elevated cells in
serum-free GSC media and examined their oncosphere
formation ability. In this context, MKP1 overexpression
resulted in a significant reduction of the efficiency of
oncosphere formation (Fig. 3f). Moreover, self-renewal
activity, measured as the number of secondary onco-
spheres was also dramatically diminished in cells with
elevated MKP1 levels (Fig. 3g). Consistent with these
results, the relative expression of GSC markers such as
CD133, SOX2, and SOX9 were decreased in oncospheres
derived from cells overexpressing MKP1 (Fig. 3h). These
results indicate that MKP1 may suppress the self-renewal
activity of GSCs. Tumor-initiating ability through limited
dilution injections in immunodeficient mice characterizes
Fig. 5 Activation of JNK and p38 MAPK is impaired by MKP1 in glioma cells. a, b Representative western blot of the effect of overexpressing
MKP1 in MAPK activity in (a) U87, U373 and (b) GNS166 cells. c Cell growth assay comparing control and MKP1-overexpressing GNS166 cells after 72 h
of treatment with p38 MAPK inhibitor SB203580 (n = 3). d Cell growth assay of U87 cells comparing control and SB203580-treated cells for 72 h (n = 3)
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functionally the self-renewing population of GSC
in vivo25. Interestingly, 100% animals injected with
2.5×105 parental or empty vector cells developed tumors
40 days later, while only 12% of MKP1-elevated cells
presented tumors. Similarly, 50% of mice harboring
2.5×104 empty vector cells generated tumors compared
to 0% with elevated MKP1 (Supplementary Fig. 3). Thus,
MKP1 overexpression exhibited a significant decrease
(p= 0.001) in the frequency of tumor-initiating cells
going from 1/60.235 control cells compared to 1/270.900
MKP1-overexpressing cells (Fig. 3i). These results
indicate that MKP1 suppresses glioma cell tumor
activity not only by inhibiting their proliferative capacity
but also decreasing their self-renewal and tumor initiation
activity.
Elevated MKP1 suppresses proliferation and self-renewal
ability of GSCs
To directly address the impact of MKP1 overexpression
in the regulation of GSCs, we stably overexpressed MKP1
in GNS166 cells. Quantitative RT-PCR confirmed effec-
tive overexpression (Fig. 4a); therefore we characterized in
detail their proliferative and stem-like cell characteristics.
Functionally, high levels of MKP1 led to a statistically
significant decrease in cell proliferation looking at both
cell numbers (Fig. 4b) and P-H3 labeling (Fig. 4c), con-
firming the relevance of MKP1 in glioma cell prolifera-
tion. To test the impact of MKP1 in GSC self-renewal and
differentiation, we studied the relative expression of sev-
eral stem cell marker genes; SOX2, SOX9, OCT4, and
GFAP finding that all of them were decreased in MKP1-
overexpressing cells by qRT-PCR (Fig. 4d), and SOX2 and
SOX9 by western blotting (Fig. 4e). On the contrary,
differentiation markers such as TUJ1 and CNPase were
upregulated at a transcriptional level (Fig. 4f), a result
further substantiated by immunofluorescence analysis in
which we found higher number of TUJ1 and CNPase-
positive cells in GNS166 overexpressing MKP1 compared
to control cells (Fig. 4g). Finally, we assessed whether
MKP1-elevated cells remained tumorigenic. For this, cells
N
um
be
r o
f c
el
ls
 x
10
4
***
*
0
20
40
60
80
5yaD3yaD1yaD0yaD
***
day0 day1 day3 day5
A
0
1
2
3
4
5
**
**
U87 U251
M
K
P
1
(fo
ld
 c
ha
ng
e)
D
0
0.2
0.4
0.6
0.8
1
1.2 control
MKP1
GNS166 U87
*
M
G
M
T
(fo
ld
 c
ha
ng
e)
FGNS166 cells + TMZ 100 μM
control
MKP1
control
TMZ 100 μM
0.0
0.2
0.4
0.6
0.8
1.0
control
MKP1
M
TT
 c
el
l v
ia
bi
lit
y 
(%
)
on
co
sp
he
re
s
(r
el
at
iv
e 
nu
m
be
r)
0
20
40
60
80
100
- +
- +
**
**
**
**
control
MKP1
B
E
U87
U87
0
50
100
150
TMZ 100 μM :
M
TT
 c
el
l v
ia
bi
lit
y 
(%
)
- +TMZ 100 μM :
C
shSC
shMKP1
TMZ 50μM :
Fig. 6 High levels of MKP1 sensitize glioma cells to temozolomide treatment. a mRNA expression of MKP1 was studied in U87 and U251 GBM
cell lines under the effect of TMZ (100 μM) for 24 h. b Cell viability comparing control and MKP1-overexpressing U87 cells under 100 μM TMZ
treatment for 72 h. c Cell viability comparing U87 cells transfected with shSC or shMKP1 cultured with 100 μM TMZ for 72 h. d Cell proliferation
comparing control and MKP1-overexpressing GNS166 cells under 100 μM TMZ treatment. e Relative oncosphere-forming capacity of indicated U87
cells in presence of 50 μM TMZ for 7 days. f MGMT mRNA levels were assayed in both control and MKP1-transduced GNS166 and U87 cells. Statistical
significance was obtained with Student’s t test (*p≤ 0.05; **p≤ 0.01; ***p≤ 0.001)
Arrizabalaga et al. Oncogenesis  (2017) 6:401 Page 7 of 14
***
**
0
5
10
15
20
*
**
*
**
0.1 0.5 1-TSA (μM):
0
2
4
6
8
U87
GNS166
0.1 0.5 1-SAHA (μM):
***
**
*
***
***
C
0.0
0.2
0.4
0.6
0.8
1.0
1.2
on
co
sp
he
re
s
(r
el
at
iv
e 
nu
m
be
r)
***
******
***
***
0.1 0.5 1-
TSA (μM)
0.1 0.5 1
SAHA (μM)
U87 D
0
1
2
3
4
5
P
-H
3+
ce
lls
 (%
)
0.5μM-
TSA 
0.5μM
SAHA 
**
**
GNS166
U87
GNS166
M
K
P
1
(fo
ld
 c
ha
ng
e)
M
K
P
1
(fo
ld
 c
ha
ng
e)
E
**
*
0
1
2
3
4
5
0.1 1-
TSA (μM)
0.1 1
SAHA (μM)
*
Oncospheres from U87
M
K
P
1
(fo
ld
 c
ha
ng
e)
**
*** ***
0
0.2
0.4
0.6
0.8
1
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
on
co
sp
he
re
s
(r
el
at
iv
e 
nu
m
be
r)
0.5 1- 0.5 1SAHA (μM):
TMZ (μM):
0.5- 0.5SAHA (μM):
-
**
**
**
GNS166U87
P
-H
3+
ce
lls
 (r
el
at
iv
e 
nu
m
be
r)
A B
I J
control
TSA 0.25
TSA 0.50
*
*
0
1
2
3
4
5
6
Fo
ld
 a
ct
iv
at
io
n 
(M
K
P
1
pr
om
ot
er
)
F
H
-- 50- -
G
50 TMZ (μM): 100
0
20
40
60
80
100
M
TT
 c
el
l v
ia
bi
lit
y 
(%
)
control
MKP1
0.1- 0.1SAHA (μM):
- 100 100-
0.5
TMZ (μM):
0.5
-
*** ***
**
***
**
***
**
* *
0.0
0.2
0.4
0.6
0.8
1.0
0.1 1.0-SAHA (μM):
- 50 50-
-
on
co
sp
he
re
s
(r
el
at
iv
e 
nu
m
be
r)
control
MKP1
TMZ (μM):
****
**
*
***
***
***
**
** ***
Fig. 7 HDAC inhibitors upregulate MKP1 in glioma cells and sensitizes to temozolomide treatment. a MKP1 mRNA levels were studied in U87
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were injected into the ventral forebrain of immunocom-
promised mice and we then monitored for symptoms of
glioma development. While 100% of animals injected with
control cells became sick and developed tumors at
4 months post injection, only 33% of animals injected with
cells overexpressing MKP1 developed tumors (Fig. 4h). In
summary, these results demonstrate that genetic over-
expression of MKP1 results in decreased self-renewal and
tumorigenic potential. Overall, these data also raise the
prospect that the induction of MKP1 could be exploited
for therapy in glioblastoma.
Activation of JNK and p38 MAPK is impaired by MKP1 in
glioma cells
MKP1 is a negative inhibitor of the activity of JNK, p38
MAPK, and ERK1/2. In an effort to identify the down-
stream molecular pathways of MKP1 activity on glioma
cells, we tested the total and phosphorylated expression of
these proteins in cells with elevatedMKP1. We did not see
marked differences in the total JNK, p38 MAPK, or ERK
expression in glioma cells (U87, U373) or in GNS166 cells
(Fig. 5a, b). However, there were notable differences with
respect to their activated forms in these cellular contexts.
First, we found that P-ERK was not altered in any of the
cell lines (Fig. 5a, b) and only slightly in U373 cells, sug-
gesting that MKP1 function on glioblastoma is not
dependent in this kinase. Next, we measured the activation
of p38 MAPK, observing contradictory results. As expec-
ted, P-p38 MAPK was decreased in GNS166 cells derived
from patients (Fig. 5b), but its expression was increased in
U87 and U373 conventional cells (Fig. 5a). We tried to
explore further this opposite activity and cultured the
different cells lines with SB203580, an inhibitor of p38
MAPK activity observing that treatment with this com-
pound significantly decreased GSCs proliferation by 35%
and to a level observed in cells overexpressing MKP1
(Fig. 5c), whereas the effect in proliferation was not sta-
tistically significant and so clear in U87 (18%) and U373
(25%) cells (Fig. 5d). Finally, we measured P-JNK activity
and found that high levels of MKP1 reduced significantly
its levels both in U87 and U373 glioma cells and GNS166
cells (Fig. 5a, b). These results suggest that JNK might be
the main effector of MKP1 activity in glioma cells.
High levels of MKP1 correlate with temozolomide
sensitivity
Glioblastomas are known to be resilient to therapy
treatment because malignant GSCs survive radiotherapy
and chemotherapy with TMZ alkylating agent first-line
treatment. We studied the impact of MKP1 in response to
TMZ treatment. First, we found that short-term exposure
to 100 µM of TMZ induced the expression of MKP1 in
U87 and U251 glioma cell lines by more than threefold
(Fig. 6a), suggesting that MKP1 levels could be involved in
response to current chemotherapy. To determine this
idea, U87 cells with ectopic elevation of MKP1 were
exposed to the same concentration of TMZ for 72 h and
cell chemosensitivity was measured by MTT assay.
Notably, U87 cells with high levels of MKP1 presented
increased sensitivity (% of viability <30%) when compared
to control cells (% of viability of 50%) in the presence of
TMZ (Fig. 6b). On the contrary, TMZ did not induce any
significant effect in U87 cells transduced with a shMKP1
(Fig. 6c), likely because the endogenousMKP1 levels were
already very low (Fig. 1a, Supplementary Fig. 4).
In order to further test the involvement of MKP1 in
temozolamide (TMZ) response, we examined the sensi-
tivity of GSCs with high levels of MKP1 to chemotherapy.
We measured the proliferative capacity of GNS166 cells in
the presence of TMZ finding that cells with elevated
MKP1 showed significant drug sensitivity and impaired
cell growth when compared to control cells (Fig. 6d). In
line with these results, the formation of oncospheres was
also significantly reduced in U87 cells with elevated
MKP1, when treated with TMZ (Fig. 6e). These findings
confirm that high levels of MKP1 increase chemosensiti-
zation to TMZ. The presence of the DNA-repair protein
MGMT leads to cellular resistance to cytotoxic actions of
TMZ, whereas methylation of the MGMT promoter
increases TMZ cellular sensitivity and increases patient
survival2, 26 Therefore, we tested whether there was a
correlation between high levels of MKP1 and MGMT
promoter status in human biopsies in vivo. The percen-
tage of MGMT methylated cases in biopsies with MKP1
high and low expression did not show statistically sig-
nificant differences in a small cohort of 42 patients (data
not shown), however, MGMT expression was decreased
in U87 and GNS166 cells stably overexpressing MKP1
compared to control cells (Fig. 6f). These results indicate
that high levels of MKP1 may function as a TMZ sensi-
bilizer in human GSCs.
HDAC inhibitors upregulate MKP1 in glioma cells
Epigenetic alterations are increasingly implicated in
glioblastoma pathogenesis and we have observed that
MKP1 levels are epigenetically modified in GSCs. Histone
deacetylase inhibitors (HDACIs) are a group of promising
epigenetic agents for glioblastoma27, which have been
shown to upregulate the expression of MKP1 in lung
cancer28. Therefore, we tested the effect of two epigenetic
agents, trichostatin A (TSA), and suberoylanilide hydro-
xamic acid (SAHA), on MKP1 expression. We observed a
remarkable increase in MKP1 with augmented doses of
both HDACIs in U87 and in GNS166 cells (Fig. 7a, b).
Importantly, this decline correlated with marked dose-
dependent reduction in oncosphere formation (over 60%)
in U87 (Fig. 7c), and decrease in the proliferative capacity
(by 50%) of GNS166 cultured with increasing
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concentrations of TSA and SAHA (Fig. 7d). Of note, the
expression ofMKP1 on the oncospheres generated in U87
cells in the presence of both HDACIs also displayed sig-
nificantly higher levels of MKP1 compared to non-treated
controls (Fig. 7e). These findings indicate that HDACIs
can inhibit both proliferative ability and oncosphere for-
mation potential of glioma cells concomitantly with ele-
vation of MKP1 expression. We further study the effect of
the HDACIs on MKP1 activity, and found that increasing
concentrations of TSA elevated the luciferase
activity of the MKP1 promoter (Fig. 7f). Moreover,
U87 cells ectopically overexpressing MKP1 generated
fewer oncospheres than control cells when treated
with 0.1 μM of SAHA (Fig. 7g). They also exhibited
decreased cell viability as measured by MTT assays
(Fig. 7h). These findings suggest that MKP1 represents a
candidate biomarker for HDAC inhibitors sensitivity in
glioblastoma.
Combined therapeutic approaches acting synergistically
have been proven more effective than individual treatments.
We therefore tested whether HDACis could represent a
potential enhancer of the cytotoxic effects of TMZ and
sensitize cells with different levels of MKP1. Accordingly,
we performed oncosphere formation assays in which U87
cells were cultured with a constant dose of 100 μM TMZ
together with 0.5 and 1 μM of SAHA (concentrations that
significantly elevated MKP1 expression). Interestingly,
combined treatment of SAHA and TMZ resulted in a
higher decline in oncosphere formation than with the single
agent alone (Fig. 7i). Moreover, we cultured GNS166 cells
with this combined therapeutical strategy finding that there
was also a synergistic anti-proliferative effect of SAHA and
TMZ in those cells (Fig. 7j). Finally, to evaluate whether the
anti-tumoral activity of the combination of SAHA and
TMZ might be directed thorough GSCs and mediated by
MKP1, we repeated the oncosphere formation and MTT
assays in control and MKP1-overexpressing U87 cells cul-
tured with SAHA and TMZ in combination. Notably,
combined treatment of SAHA and TMZ formed sig-
nificantly lower number of oncospheres and reduced cell
viability from MKP1-overexpressing cells than with single
agents alone or from control cells (Fig. 7g, h). Overall, our
results demonstrate that combined treatment of HDACis
and TMZ achieved a strong anti-tumoral effect and identify
MKP1 as a novel biomarker for this therapeutic strategy.
Discussion
In this study, we have identified that MKP1/DUSP1
expression is heterogeneous within low- and high-grade
gliomas and particularly in glioblastoma samples.
Importantly, we have demonstrated that the subset of
biopsies overexpressing MKP1 levels is associated with
the subgroup of patients with elevated median overall
survival. Remarkably, this expression and clinical
relevance is differential in relation to additional types of
cancer with opposite expression. Indeed, the role of
MKP1 in cancer is mostly correlated with carcinogenesis,
high expression levels of MKP1 promoting tumorigenesis
in prostate, pancreatic, colon, bladder, gastric, breast, and
lung cancer20, 21, 29–33. Moreover, MKP1 has also been
positively related to tumor progression in lung cancer (by
downregulating JNK and p38 kinases)21, 34, in breast
cancer by inducing epithelial mesenchymal transition and
PKC pathway, and in hepatocellular carcinoma by inhi-
biting ERK activity35. On the other hand, a few studies
have reported a negative role of MKP1 in carcinogenesis,
such as in hepatocellular carcinoma and head and neck
cancer35–38, similar to the situation we find with
glioblastomas.
TMZ is currently the most effective chemotherapy for
glioblastoma. Indeed, its incorporation in the clinic
extended patient median survival from ~12 to
15 months2, 39. Damage generated by TMZ can be
repaired by MGMT, thus inducing treatment resistance,
while methylation of the MGMT promoter leads to an
increase in TMZ sensitivity26. Our results show that
MKP1 is overexpressed in response to TMZ and cells with
elevated levels of MKP1 express lower levels of MGMT.
Moreover, functional studies in cells ectopically over-
expressing or silencing MKP1 confirm that cells with
elevated levels of MKP1 are more sensitive to TMZ
explaining the correlation observed between high levels of
MKP1 and elevated patient survival in clinical biopsies.
These results also support the fact that MKP1 activity is
context-dependent, because its high levels induce therapy
resistance in other types of cancers such as lung (to cis-
platin), ovary (cisplatin)20, pancreatic (gemcitabine)40,
breast (taxanes)41, and U937 cells (radiation)42. The
resistance against different therapies is related in most of
the tumors to the downregulating activity of MAP kina-
ses, JNK, and p38 MAPK, which are required for induc-
tion of apoptosis after those treatments20. In glioma cells,
MKP1 activity appears to be related to GSC activity
because we have observed a positive correlation between
GSC differentiation and its elevated levels.
In addition to an association between higher levels of
MKP1 expression in biopsies with overall higher survival
rates of patients with glioblastomas, we showed that
genetic overexpression of MKP1 in glioma cells and
directly in the GSC population decreases proliferative
ability, causes depletion of self-renewal, and subsequently
decreases tumor initiation and progression. We also
identified thatMKP1modulates glioma cell heterogeneity.
In agreement with this, we observed enrichment ofMKP1
in differentiated GSC upon treatment with BMP4 and
serum addition, induction of GSC differentiation in
MKP1-overexpressing cells and modulation of its
expression in cells with altered activity of SOX2 and
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SOX9, well-established stem cell genes and regulators of
GSC activity43. Our results indicate that the activity of
MKP1 is negatively involved in GSC maintenance likely
regulating the interplay between proliferation, self-
renewal, and differentiation. These activities are likely to
be mediated by SOX factors and JNK kinase. Indeed, we
identified that there is an inverse correlation between
MKP1 and SOX9 and SOX2 expression in glioblastoma
samples. Moreover, we have found that high levels of
MKP1 in glioma cells and also GSCs, downregulate JNK
phosphorylation. Notably, increased JNK phosphorylation
is related with the tumor-initiating capacity of GSC and
carcinogenesis44. Along the same lines, activation of the c-
jun/MELK pathway has been reported to maintain GSCs
in immature stage and facilitate radiotherapy resistance45.
In addition to transcriptional regulation via SOX2 and
SOX9 stem cell factors, the activity of MKP1 is also
affected by epigenetic changes. Indeed, we have observed
that the MKP1 promoter is demethylated upon BMP4
differentiation treatment. Similarly, pharmacological
demethylation with 5-aza also increases the expression of
MKP1. These findings are supported with the evidence
that, during carcinogenesis, the epigenome of cancer cells
undergoes multiple alterations that facilitate cell plasticity
and are relevant for cancer progression46.
Since elevated levels ofMKP1 have been associated with
overall extended survival of patients, TMZ chemosensi-
tivity, and GSC differentiation, our results suggest that
targeting the activity of MKP1 (through induction) may
offer a new promising therapeutic treatment modality in
glioblastoma (Fig. 8). Previous investigators have observed
that MKP1 levels are elevated with Notch inhibitors (γ
secretase) and HDACIs28, 47. In an effort to identify drugs
or molecules that might activate efficiently the expression
of MKP1, we tested the latter using two different com-
pounds (TSA and SAHA). Notably, we observed that
MKP1 expression is regulated by epigenetic modifications
in glioma cells and, HDACIs are a group of epigenetic
molecules with promising results in pre-clinical and
clinical trials in gliomas and in particular with glio-
blastomas27, 48, and some (SAHA, romidepsin and belli-
nostat) have received approval from the FDA for the
treatment of cutaneous T-cell lymphoma. We found that
TSA and SAHA increased significantly, between 2 and 15-
fold, the expression of MKP1. The elevated expression
level detected by qRT-PCR may be due to an increased
activity of the MKP1 promoter. The increase was dose-
dependent and already apparent at low doses. Moreover,
the citotoxic activity of HDACIs is higher in cells with
elevated MKP1 expression postulating it as a biomarker
for these compounds. These results are particularly
important in the case of SAHA, which is being tested in
clinical trials for glioblastoma alone or in combination
with current therapy treatments, such as TMZ or
radiotherapy27. Our results demonstrate that the
pharmacological overexpression of MKP1 may be feasible
using inhibitors of HDACs and could be relevant for these
trials.
It is important to note that our results and previous
investigations demonstrate that these agents impair self-
renewal activity, induces differentiation, and subsequently
decreases tumorigenic activity49, 50. Given that increased
Fig. 8 Schematic image representing the function of MKP1 on glioma stem cell (GSC) activity and glioblastoma progression. Glioblastoma is
a heterogeneous tumor with a population of GSCs (in blue, chemo-, and radiotherapy-resistant) with low levels of MKP1. Genetic MKP1
overexpression or its upregulation with HDACIs increases differentiation, impairs tumor growth, and sensitizes cell to TMZ indicating that elevation of
MKP1 might be and interesting approach to extend patient survival and avoid tumor recurrence
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MKP1 expression also induces sensitivity to TMZ, a
combined treatment of HDACIs and TMZ might result in
improved response to therapy in gliomas. Indeed, we
observed a synergestic anti-tumor effect of the combina-
tion of TMZ and SAHA, which is more prominent as
higher are the cellular levels of MKP1. These results
support previous glioblastoma pre-clinical studies51 and
suggest that MKP1 represents a candidate biomarker for
this therapeutic strategy in glioblastoma. Overall, our data
identifies MKP1 as a central player in glioblastoma, since
it modulates GSC activity. In fact it has a dual role as it
acts as an inhibitor of proliferation and promoter of dif-
ferentiation (Fig. 8). These data provide further evidence
for the development of HDACIs as potential therapeutics
against this type of cancer, particularly in combination
with TMZ and using MKP1 as a biomarker and a strong
rationale for the development of novel strategies targeting
MKP1 for glioblastoma.
Materials and methods
Patients and tumor samples
Human glioblastoma samples and patient clinical
information were obtained from Hospital Valencia
(cohort 1) and Donostia University Hospital (cohort 2).
The study included biopsies from 44 patients seen in
Valencia and 25 in San Sebastian, and diagnosed as pri-
mary glioblastoma grade IV according to the WHO cri-
teria. Basque Biobank for Research O+EHUN http://
www.biobancovasco.org provided the cohort 2. All study
participants signed informed consent forms approved by
the Institutional Ethical Committee. The study was
approved by the ethic committee of Biodonostia Institute
and Hospital Donostia.
Cell lines, cultures, and reagents
Glioma cell lines U87MG (U87), U373MG (U373),
U251MG (U251), A172, and T98G were purchased from
the ATCC. The cell lines were cultured in DMEM
(Gibco), supplemented with 10% FBS (Gibco), 100 U/ml
penicillin, and 100 µg/ml streptomycin for traditional
monolayer cultures or in in GSC medium consisting of
DMEM/F-12 (Sigma) supplemented with N2,
B27 supplements (Fisher) and growth factors (20 ng/ml
basic fibroblast growth factor (bFGF), and 20 ng/ml epi-
dermal growth factor (EGF)) (Sigma) for oncosphere
cultures, similarly to glioblastoma primary tumors. Cells
were maintained at standard conditions of 37 °C, 5% CO2
in humidified atmosphere, were dissociated, and cells
grown in oncosphere medium for 10 days. Differentiation
assays were performed by adding 1% FBS to the DMEM-
F12 complete medium. Temozolomide (TMZ) (Sigma),
SB203580 (Selleckchem), SAHA (Cayman), TSA (Sigma),
and 5-Aza-2′-deoxycytidine (5-AZA) (Sigma) were dis-
solved in DMSO.
Oncosphere assays
U87 and U373 were grown in GSCs medium for
10 days. These oncospheres were then disaggregated with
accutase (Gibco), and seeded for secondary (2ry) onco-
spheres and maintained for another 10 days. For quanti-
fication studies, 500 cells per well were seeded in non-
treated 12-wells flat bottom plates and fresh media was
added every 3 days to the plate. After 10 days, onco-
spheres were counted. Same procedure was performed for
2ry oncosphere assay.
Lentiviral infections and Luciferase assays
Infections were performed as previously described30.
For stable overexpression of MKP1, the retroviral plasmid
pLXSN MKP1 was used, whereas pGIPZ scrambled
(shSC) empty vector and pGIPZ shMKP1 were used for
silencing experiments. For stable overexpression of SOX2
and SOX9, pLM-mCitrine-SOX2 (a gift from Ander Izeta,
Biodonostia Institute) and pWXL SOX9 (a gift from Bob
Weinberg, Addgene plasmid 36979) lentiviral constructs
were used. For SOX2 or SOX9 knockdown, cells were
infected with pLKO.1 shSOX2 (a gift from M. Meyerson,
Addgene plasmid 26353), shSOX9 (a gift from B. Wein-
berg, Addgene plasmid 1855), or empty vector. Infected
cells were selected in the presence of 2 μg/ml puromycin
or 1.5 μg/μl of geneticine depending on the selectable
marker of the plasmid and then maintained with 0.2 μg/
ml puromycin or geneticine (Sigma).
For luciferase assays, U87 cells were transfected with a
MKP1-promoter luciferase construct (pGL3 MKP1)
(250 ng), and cultured with increasing concentrations of
TSA. The relative luciferase activity was determined
after 48 h of transfection using the dual-Luciferase
reporter assay system (Promega). Results are average of
three independent experiments (each sample is by
triplicate in each experiment) and expressed as mean
values± SD).
RNA analysis
Total RNA was extracted with Trizol (Life Technolo-
gies). Reverse transcription was performed using random
priming and Superscript Reverse Transcriptase (Life
Technologies). Quantitative real-time PCR was performed
using Absolute SYBR Green mix (Thermo Scientific) in an
ABI PRISM 7300 thermocycler (Applied Biosystems).
Variations in input RNA were corrected by subtracting
the number of PCR cycles obtained for GAPDH.
Western blot analysis
Immunoblots were performed following standard pro-
cedures. The antibodies for detection of SOX2 (AB5603
Millipore), SOX9 (AB5535 Millipore), p-p38 (9211 Cell
Signalling), p38 (sc-7972 Santa Cruz), p-JNK (9251 Cell
Signalling), JNK (sc-474 Santa Cruz), p-ERK1/2 (9101 Cell
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Signalling), ERK1/2 (9102 Cell Signalling), and ß-actin (AC-
15 Sigma) were used in the study. For secondary antibodies,
we used horseradish peroxidase (HRP)-linked anti-rabbit or
anti-mouse (SantaCruz Biotechnology), both at a 1:2000
dilution. Detection was performed by chemiluminescence
using NOVEX ECL Chemi Substrate (ThermoFisher).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 15 min,
and washed with phosphate-buffered saline (PBS) sup-
plemented with 0.3% Triton X-100 and 1% FBS, for 5 min
at 4 °C. Subsequent to blocking for 1 h with PBS and 1%
FCS, cells were incubated with p-Histone3 (P-H3),
(ab14955 Abcam), neuron-specific class III beta-tubulin
(TUJ1), (MMS-435P Covance), cyclic nucleotide phos-
phodiesterase (CNPase), (MAB326 Millipore) antibodies
for 2 h. Secondary antibody was Alexa Fluor 555 rabbit
anti-mouse IgG. Nuclear DNA was stained with 4′,6-
diamidino-2-phenylindole (DAPI) (Sigma).
Immunohistochemistry
For immunohistochemistry, tumor sections were incu-
bated with primary antibody for Ki67, ab15580, Abcam.
Sections then were incubated with MACH 3 Rabbit Probe
and MACH 3 Rabbit HRP-Polymer (M3R531, Biocare
Medical).
In vivo carcinogenesis and survival assays
All process involving animals were subjected to
approval by the Research Animal Care of Biodonostia
Institute. U87 cells were collected with trypsin/EDTA and
resuspended in PBS before subcutaneous injection. For
tumor initiation, 2.5x105 and 2.5x104 cells were injected
subcutaneously into both flanks of Foxn1nu/Foxn1nu nude
mice (8 weeks old and randomly selected) and frequency
of tumor initiation was measured with ELDA. For tumor
growth, mice were observed on a weekly basis and
external calipers were used to measure tumor size, and
from these measurements, tumor volume was estimated
by V= L×W2×0.5; where L is the tumor length and W is
the tumor width. The investigator was blinded to the
group allocator. For xenotransplantation, GNS166 cells
were injected stereotactically into the frontal cortex of
6–8-week-old NOD-SCID mice. Briefly, GSCs were dis-
aggregated with accutase (Gibco) and resuspended in PBS.
Cells of 1×105 were injected into the putamen using a
stereotaxic apparatus. Survival distributions were deter-
mined using the log-rank test and GraphPad Prism
5 software.
Data analysis
Results are represented as mean values± SEM, indi-
cating the number of experiments carried out for each
assay. Statistical significance has been calculated using
Student’s t test, (*p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001), or
the log-rank test for Kaplan–Meier survival analyses.
Additional tests are included in the text.
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